MECHANISMS FOR THE FORMATION MYOCARDIAL FIBROSIS IN NORM AND IN CERTAIN CARDIOVASCULAR DISEASES, HOW TO DIAGNOSE IT
https://doi.org/10.21518/2079-701X-2017-12-75-81
Abstract
The review summarizes current knowledge regarding the origins and role of myocardial fibrosis formation, including the effects of humoral and cellular components. The concepts of extracellular matrix and volume, their clinical significance for the progression of cardiovascular diseases, the background for the formation of new approaches for the treatment of cardiac pathology are considered, taking into account the results of determination of extracellular volume with the help of MRI.
About the Authors
S. V. Miklishanskaya
Russian Medical Academy of continuing post-graduate studies
Russian Federation
Russian Federation
PhD in medicine
N. A. Mazur
Russian Medical Academy of continuing post-graduate studies
Russian Federation
Russian Federation
MD, Prof.
N. V. Shestakova
Russian Medical Academy of continuing post-graduate studies
Russian Federation
Russian Federation
PhD in medicine
References
1. Глотов М.Н., Мазур Н.А. Диастолическая функция левого желудочка у больных гипертонической болезнью: Обзор. Кардиология. 1994; 1-2:89-93.
2. Хежева Ф.М., Мазур Н.А. Сывороточные маркеры фиброза у больных артериальной гипертонией. Кардиология. 2006; 3:64-67.
3. Мазур Н.А. Органные поражения, нарушения метаболизма при артериальной гипертонии и влияние на них гипотензивной терапии. Тер. архив. 1995; 67: 3-5.
4. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart Failure With Preserved Ejection Fraction Molecular Pathways of the Aging Myocardium. Circ Res. 2014; 115: 97-107.
5. Овчинников А.Г., Ожерельева М.Г., Агеев Ф.Т. Фиброз левого желудочка: патогенез, диагностика, лечение. Неотложная кардиология. 2015; №4: 11-26.
6. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015 66, NO. 8, 943-959.
7. Ivey M J, Tallquist MD. Defining the Cardiac Fibroblast. Circ J. 2016; 80: 2269–2276.
8. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010; 225: 631–637.
9. Fu J, Srivastava D. Direct Reprogramming of Fibroblasts into Cardiomyocytes for Cardiac Regenerative Medicine. Circ J. 2015; 79: 245– 254.
10. Baum J, Duffy HS. Fibroblasts and myofibro-blasts: what are we talking about? J Cardiovasc Pharmacol. 2011; 57: 376–379.
11. Yong KW, Li Y, Huang G et al. Mechanoregulation of cardiac myofibroblast differentiation: implications for cardiac fibrosis and therapy. Am J Physiol Heart Circ Physiol. 2015; 309: H532–H542.
12. Vasquez C, Benamer N, Morley GE. The Cardiac Fibroblast: Functional and Electrophysiological Considerations in Healthy and Diseased Hearts. J Cardiovasc Pharmacol. 2011; 57(4): 380–388.
13. Cartledge JE, Kane C, Dias P, et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res. 2015; 105: 260–70.
14. Takeda N, Manabe I. Cellular Interplay between cardiomyocytes anda nonmyocytes in cardiac remodeling. Int J Inflam. 2011; 2011: 535241.
15. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–45.
16. Wynn Т.А. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199–210.
17. Lawrie CH. Micro RNAs in Medicine. Wiley-Blackwell. 2013, p.720.
18. Yilmaz A, Kindermann I, Kindermann M et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences incomplication rate and diagnostic performance. J Circulation. 2010; 122: 900-909.
19. Moon JC, Messroghli DR, Kellman P et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. Journal of Cardiovascular Magnetic Resonance. 2013, 15:92.
20. Treibel TA, Zemrak F, Sado DM et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Journal of Cardio vascular Magnetic Resonance. 2015; 17:74-86.
21. Everett RJ, Stirrat CG, Semple SIR et al. Assessment of myocardial fibrosis with T1 mapping MRI. Clinical Radiology. 2016; 8: 768-778.
22. Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013; 6: 672–683.
23. Li Q, Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Comm. 2014; 452: 497–502.
24. Wu J, Xia S, Kalionis B et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014; 2014: 615312.
25. Boon RA, Iekushi K, Lechner S et al. Micro-RNA-34a regulates cardiac ageing and function. Nature. 2013; 495: 107–110.
26. Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circulation: Cardiovascular Imaging 2017;10:e005619.
27. Travers JG, Kamal FA, Robbins J et al. Cardiac Fibro sis: The Fibroblast Awakens. Circ Res. 2016; 118: 1021–1040.
Review
For citations:
Miklishanskaya SV, Mazur NA, Shestakova NV. MECHANISMS FOR THE FORMATION MYOCARDIAL FIBROSIS IN NORM AND IN CERTAIN CARDIOVASCULAR DISEASES, HOW TO DIAGNOSE IT. Meditsinskiy sovet = Medical Council. 2017;(12):75-81. (In Russ.) https://doi.org/10.21518/2079-701X-2017-12-75-81
Views:
800
Email this article 